Case Studies

PharmaMar (PHM.BME): Investor Relations Program

June 7, 2022

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of PharmaMar’s product Zepzelca® (lurbinectedin) in 2020 by partner Jazz Pharmaceuticals as a second-line treatment for SCLC, the Zepzelca® story struggled to gain traction with investors and the broader PharmaMar investment…

Read More

Valneva NASDAQ IPO (Dual-Listing) Case Study

May 20, 2022

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of promising COVID-19, Lyme Disease, and Chikungunya vaccines. LifeSci worked to raise Valneva’s visibility among the investment community and position Valneva for a successful US dual-listing and global equity offering.  …

Read More

Inspire Medical – KOL Event and Platform Drive Visibility Prior to IPO

October 12, 2021

Inspire Medical became a LifeSci Advisors client pre-IPO. The teams collaborated to develop and execute a robust, best-in-class investor relations program to engage the investment community The Process A successful strategically timed KOL event before going live on the IPO was well attended by investors and sell-side analysts, attracting potential investors new to the story…

Read More